

Sex-Based Genetic Association Study Identifies *CELSR1* as a Possible Chronic Obstructive Pulmonary Disease Risk Locus among Women

Megan Hardin^{1,2}, Michael H. Cho^{1,2}, Sunita Sharma³, Kimberly Glass¹, Peter J. Castaldi¹, Merry-Lynn McDonald¹, Hugues Aschard⁴, Jody Senter-Sylvia¹, Kelan Tantisira^{1,2}, Scott T. Weiss^{1,2}, Craig P. Hersh^{1,2}, Jarrett D. Morrow^{1,2}, David Lomas⁵, Alvar Agusti⁶, Per Bakke⁷, Amund Gulsvik⁸, George T. O'Connor⁹, Josée Dupuis^{10,11}, John Hokanson¹², James D. Crapo¹³, Terri H. Beaty¹⁴, Nan Laird⁴, Edwin K. Silverman^{1,2}, Dawn L. DeMeo^{1,2}, and the COPDGene and Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points Investigators

¹Channing Division of Network Medicine and ²Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; ³Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado; ⁴Harvard School of Public Health, Boston, Massachusetts; ⁵Department of Medicine, University College London, London, United Kingdom; ⁶Thoracic Institute, Hospital Clinic, Barcelona, Spain; ⁷Department of Clinical Science, University of Bergen, Bergen, Norway; ⁸Department of Geriatric Medicine Ullevaal, Institute of Clinical Medicine, Oslo University Hospital University of Oslo, Oslo, Norway; ⁹Boston University School of Medicine, Boston, Massachusetts; ¹⁰Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts; ¹¹National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts; ¹²Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Denver, Colorado; ¹³Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Health, Denver, Colorado; and ¹⁴Johns Hopkins School of Public Health, Baltimore, Maryland

Abstract

Chronic obstructive pulmonary disease (COPD) is a complex disease with strong environmental and genetic influences and sexually dimorphic features. Although genetic risk factors for COPD have been identified, much of the heritability remains unexplained. Sex-based genetic association studies may uncover additional COPD genetic risk factors. We studied current and former smokers from COPD case-control cohorts (COPDGene non-Hispanic whites and African Americans, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points, and Genetics of Chronic Obstructive Lung Disease). COPD was defined as post-bronchodilator forced expiratory volume in 1 second/forced vital capacity less than 0.70 and forced expiratory volume in 1 second percent predicted less than 80. Testing was performed across all cohorts and combined in a meta-analysis adjusted for age, pack-years, and genetic ancestry. We first performed genome-wide single-nucleotide polymorphism (SNP)-by-sex interaction testing on the outcome of COPD affection status.

We performed sex-stratified association testing for SNPs with interaction P less than 10^{-6} . We examined over 8 million SNPs in four populations, including 6,260 subjects with COPD (40.6% female) and 5,269 smoking control subjects (47.3% female). The SNP rs9615358 in the cadherin gene *CELSR1* approached genome-wide significance for an interaction with sex ($P = 1.24 \times 10^{-7}$). In the sex-stratified meta-analysis, this SNP was associated with COPD among females (odds ratio, 1.37 [95% confidence interval, 1.25–1.49]; $P = 3.32 \times 10^{-7}$) but not males (odds ratio, 0.90 [95% confidence interval, 0.79–1.01]; $P = 0.06$). *CELSR1* is involved in fetal lung development. In a human fetal lung tissue dataset, we observed greater *CELSR1* expression in female compared with male samples. This SNP-by-sex genome-wide association analysis identified the fetal lung development gene, *CELSR1*, as a potential sex-specific risk factor for COPD. Identifying sex-specific genetic risk factors may reveal new insights into sexually dimorphic features of COPD.

Keywords: chronic obstructive pulmonary disease; genetics; growth and development; sex; genome-wide association study

(Received in original form June 2, 2016; accepted in final form November 8, 2016)

This work was supported by National Institutes of Health/National Heart, Lung, and Blood Institute (NHLBI) grants K12 HL120004 (M.H.), R01HL113264 (M.H.C.), R01 HL089856 (E.K.S.), R01 HL 089897 (E.K.S. and J.D.C.), P01HL105339 (M.H.C. and E.K.S.), HL089438 (D.L.D.), and NHLBI contract HHSN268201500001I (G.T.O'C. and J.D.); this project was also supported by the 2013 Sheila J. Goodnight, M.D., F.C.C.P., Clinical Research Grant in Women's Lung Health (M.H.); the COPDGene project (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Siemens, and Sunovion.

The content of this article is solely the responsibility of the authors, and does not necessarily represent the official views of the NHLBI or the National Institutes of Health.

Am J Respir Cell Mol Biol Vol 56, Iss 3, pp 332–341, Mar 2017

Copyright © 2017 by the American Thoracic Society

Originally Published in Press as DOI: 10.1165/rcmb.2016-0172OC on November 17, 2016

Internet address: www.atsjournals.org

Clinical Relevance

There is accumulating evidence that the susceptibility to and severity of chronic obstructive pulmonary disease (COPD) is sexually dimorphic, but the biologic drivers of COPD-related dimorphism are poorly understood. Identifying sex-specific genetic associations for COPD may highlight new genes and pathways to consider for sex-specific diagnostic and therapeutic approaches to COPD.

Chronic obstructive pulmonary disease (COPD) is a complex disease characterized by fixed airflow obstruction that results from a combination of genetic risk factors and environmental exposures. COPD was the third leading cause of death in the US in 2011 (1). Although traditionally considered a disease of men, the prevalence of COPD is increasing among female smokers (2). Furthermore, there has been a growing recognition that men and women may have differing susceptibility and presentation of disease. On average, compared with males, females with COPD are more likely to report dyspnea and cough (3), and have less radiographic emphysema, but more airway remodeling (4). We have recently demonstrated that, in the COPDGene population, on average, women with COPD have less radiographic emphysema than men for the same degree of lung function, but, among subgroups with severe or early-onset COPD, women have equivalent emphysema despite less pack-years smoking (5). Women are more prevalent in populations with severe, early-onset COPD (6, 7), and women who smoke demonstrate greater lung function decline than men (8).

Cigarette smoking is the strongest environmental risk factor for COPD;

however, the variability in clinical response to smoke exposure and the familial aggregation of airflow obstruction support a genetic component as well. Although several genetic risk factors for COPD have been identified through genome-wide analysis (9), to our knowledge, no study has investigated sex-specific associations for COPD. Our aim was to identify sexually dimorphic genetic risk factors for COPD, with the goal of revealing new insights into COPD susceptibility and severity.

Genotype-by-sex interaction is likely a major component of many human traits and diseases (10, 11), including waist:height ratio (12), type II diabetes (13), and asthma (14). The genetic composition of the autosomes is shared between men and women, and, therefore, these differences likely result from variation at the level of the regulatory genome (10).

There is evidence to suggest that, similar to the complex traits mentioned previously here, COPD may also have sexually dimorphic genetic features. Lung function (the ratio of forced expiratory volume in 1 second [FEV₁] to forced vital capacity [FVC]) demonstrated sexually dimorphic heritability estimates in a population of nonsmokers (15). There is a female predominance of early-onset COPD, and female, smoking, first-degree relatives of subjects with early-onset COPD demonstrate greater lung function impairment compared with male first-degree relatives (6). In a cohort of subjects with alpha-1 antitrypsin deficiency, variants in the COPD risk gene region *CHRNA3/IREB2* demonstrated a significant single-nucleotide polymorphism (SNP)-by-sex interaction for lung function outcomes, with a significant association among males, but not females (16). Collectively, these sex-based differences in COPD susceptibility and presentation support a role for genetic influences on sexually dimorphic features.

We hypothesized that genome-wide association testing that specifically accounts for sex-specific genetic effects would identify new variants associated with COPD, as well as demonstrate sexually dimorphic association in known COPD risk alleles. We tested this hypothesis using four large case-control populations of COPD to detect a SNP-by-sex interaction for the outcome, COPD affection status.

Materials and Methods

Study Subjects

Study subjects were current or former smokers with at least 10 pack-years smoking participating in previously described case-control COPD studies: COPDGene non-Hispanic white and African American (17), ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points) (18), and Genetics of Chronic Obstructive Lung Disease (GenKOLS) subjects (19). All subjects completed standardized spirometry (20). Cases had moderate to severe airflow limitation (Global Initiative for Chronic Obstructive Lung Disease spirometry grades II–IV) with post-bronchodilator FEV₁/FVC less than 0.70 and FEV₁ less than 80% predicted. Control subjects were current or former smokers with normal lung function. Subjects with known alpha-1 antitrypsin deficiency were excluded. COPDGene subjects included non-Hispanic white or African American subjects, and these subgroups were analyzed independently of each other. ECLIPSE and GenKOLS subjects were white of European descent. All subjects signed informed consent before participation in any study activity, and Institutional Review Board approval was obtained from all study sites (see Table E5 in the online supplement; COPDGene, 2007P000554; ECLIPSE, 2005P002467; GenKOLS, 2009P001700).

Author Contributions: M.H., M.H.C., and D.L.D. participated in study conception and design, data acquisition, analysis of data, interpretation of analysis results, manuscript drafting, and manuscript editing for intellectual content; S.S. participated in data acquisition, analysis of data, interpretation of analysis results, manuscript drafting, and manuscript editing for intellectual content; H.A., C.P.H., J.D.M., G.T.O'C., J.D., T.H.B., N.L., K.G., P.J.C., P.B., and E.K.S. participated in study design, data acquisition, interpretation of analysis results, and manuscript editing for intellectual content; M.-L.M., J.S.-S., K.T., S.T.W., D.L., A.A., A.G., J.H., and J.D.C. participated in data acquisition and manuscript editing for intellectual content.

Correspondence and requests for reprints should be addressed to Dawn L. DeMeo, M.D., M.P.H., Channing Division of Network Medicine, Brigham and Women's Hospital, 181 Longwood Avenue, Boston, MA 02115. E-mail: redld@channing.harvard.edu

This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org

Genotyping

Genotyping using Illumina genome-wide SNP platforms, quality control, and imputation have been previously described for all populations (19, 21, 22). Imputation was performed using 1,000 genomes phase I v3 European (EUR) for non-Hispanic white ancestry, and cosmopolitan reference panels for African Americans.

Statistical Analysis

We first modeled the interaction between SNP and sex for COPD case-control status. We performed a separate logistic regression analysis in each population using probABEL v0.4.5 (23), testing for a significant SNP-by-sex interaction adjusting for age, sex, pack-years smoking and principal components. We combined these results in a meta-analysis using METAL (metal-2010-02-08-patch2). We then performed sex-stratified genome-wide association study (GWAS) for SNPs that demonstrated SNP-by-sex interactions. We chose an inclusion threshold of P less than 10^{-6} for carrying forward interaction SNPs, as standard significance thresholds may miss SNPs of interest.

We performed sex-stratified GWAS in all cohorts, adjusting for age, pack-years, and principal components using PLINK v1.9 (<https://www.cog-genomics.org/plink2>) (24), and combined these results in stratified meta-analyses using METAL (version 2010-08-01) (25).

We examined variants previously identified through GWAS as COPD risk factors for a SNP-by-sex interaction (*CHRNA3*, rs4416442; *FAM13A*, rs12914385; *HHIP*, rs13141641; *RIN3*, rs754388; *MMP3/12*, rs626750; *TGFB2*, rs4846480) (9), as well as sex-specific association with COPD affection status. We created regional association plots using LocusZoom (v.1) (26) and measured linkage disequilibrium using SNAP (27).

Human Fetal Lung Gene Expression Profiling

Postconception age- and sex-matched human fetal lung tissue samples from 366 samples were acquired through the tissue retrieval program sponsored by the National Institute of Child Health and Development (Rockville, MD), the University of Maryland Brain and Tissue Bank for Developmental Disorders (Baltimore, MD), and the Center

for Birth Defects Research (University of Washington, Seattle, WA), as previously described (28). Total mRNA was isolated using the Illustra RNAspin mini RNA isolation kit (GE Healthcare, Piscataway, NJ), and genome-wide gene expression profiles were measured using HumanRef8 v2 BeadChips (Illumina, San Diego, CA). Placental cotinine was measured, and only fetal lung tissues without intrauterine smoke exposure were included (29).

Sex-Specific Differences in *CELSR1* and *FAR2* Expression during Human Lung Development

We assessed sex-specific differential expression of *CELSR1* and *FAR2* genes using linear models with adjustment for postconception age.

Expression Quantitative Trait Loci Analysis

To identify a functional role for top SNPs from the SNP-by-sex interaction, we tested our top SNPs as expression quantitative trait loci (eQTL) using a previously reported analysis identifying whole-blood eQTLs from 121 subjects (40 female, 81 male) with COPD (30).

Sex-Specific Differences in *CELSR1* Expression in Adult Human Lung Tissue

We performed a sex-specific gene expression analysis for *CELSR1* using data from adult human lung tissue samples from 111 subjects with COPD and 40 control smokers with normal lung function (extended methods available in the online supplement). We assessed sex-specific differential expression of the *CELSR1* gene among subjects with COPD and control subjects using linear models with adjustment for age, race, and pack-years of smoking.

Sex-Specific Association of *CELSR1* in Lifetime Never-Smokers

We also investigated the association of *CELSR1* with obstructive lung disease in 2,229 lifetime never-smokers from the Framingham Heart Study population.

The Framingham Heart Study includes spirometry measures of three generations of family members. For the replication analysis of *CELSR1* associations, offspring cohort members and the third generation were included. A total of 2,229 individuals were

lifetime never-smokers, had genotyping and spirometry data, and met the definition of COPD ($n = 100$, 44 females, $FEV_1/FVC < 0.7$ and $FEV_1 < 70\%$ predicted) or control ($n = 2,129$, 1,156 females, FEV_1/FVC ratio ≥ 0.7 and $FEV_1 > 80\%$ predicted). Framingham participants were genotyped using the Gene Chip Human Mapping 500K Array Set (Affymetrix, Santa Clara, CA). All four SNPs selected for replication (rs9615358, rs9615981, rs9615982, and rs7286446) in the Framingham Heart Study nonsmokers were imputed using the Haplotype Reference Consortium panel. Imputation quality was good ($r^2 = 0.92$ for all four SNPs). Logistic regression models were fitted using generalized estimating equations to account for familial correlation, with COPD affection status as the outcome, and included age, sex, SNP, and a SNP-by-sex interaction term.

Results

Demographics

There were 6,260 cases with COPD (40.6% female) and 5,269 smoking control subjects (47.3% female) included in this GWAS analysis (Table 1). Males tended to have greater pack-years smoking history. Lung function was similar among male and female cases, except for lower lung function in males from ECLIPSE. Lung function was similar between male and female control subjects (Table 1).

SNP-by-Sex Interaction

Over 4.7 million genotyped and imputed SNPs across all four cohorts were included in the interaction GWAS and meta-analysis (as shown in Figure E1 in the online supplement). We identified several variants that approached the prespecified significance threshold of 5×10^{-8} for an interaction with sex (Table 2). The SNP, rs9615358, in the gene *CELSR1* had the lowest P value ($P = 1.24 \times 10^{-7}$) for the SNP-by-sex interaction.

The SNP, rs7294481, located upstream from the gene *FAR2* approached significance for the SNP-by-sex interaction ($P = 3.00 \times 10^{-7}$). A SNP near the gene, *C9orf123* approached significance for an interaction ($P = 2.95 \times 10^{-7}$); however, the direction of effect was not the same in all studies, and this SNP was not followed up.

Table 1. Subject Demographic Data

	Control Subjects			Cases		
	Male	Female	P Value	Male	Female	P Value
COPDGene non-Hispanic white						
n	1,250	1,284		1,566	1,246	
Age, yr, mean (SD)	59.5 (8.8)	59.5 (8.7)	0.86	65.1 (8.1)	64.1 (8.2)	0.002
Pack-years, mean (SD)	40.8 (21.5)	35.0 (18.7)	<0.001	60.9 (30.2)	50.5 (23.7)	<0.001
Current smokers, n (%)	529 (42.3)	475 (37.0)	0.007	544 (34.7)	432 (34.7)	1.0
FEV ₁ pp, mean (SD)	96.9 (11.2)	96.7 (10.8)	0.74	49.1 (18.2)	50.3 (17.8)	0.08
FVCpp, mean (SD)	94.96 (11.16)	95.91 (11.1)	0.03	75.84 (17.36)	76.59 (16.78)	0.25
FEV ₁ /FVC, mean (SD)	77.36 (4.89)	78.33 (4.96)	<0.001	47.72 (13.47)	49.77 (13.1)	<0.001
COPDGene African American						
n	1017	732		453	368	
Age, yr, mean (SD)	52.5 (5.5)	53.3 (6.7)	0.01	58.8 (8.0)	59.2 (8.3)	0.47
Pack-years, mean (SD)	36.2 (18.9)	36.6 (21.7)	0.70	45.5 (23.9)	38.6 (21.4)	<0.001
Current smokers, n (%)	907 (89.2)	622 (85.0)	0.01	296 (65.3)	204 (55.4)	0.005
FEV ₁ pp, mean (SD)	98.9 (12.3)	97.7 (12.0)	0.05	51.7 (18.2)	52.8 (17.2)	0.41
FVCpp, mean (SD)	98.86 (12.9)	97.27 (12.6)	0.01	76.49 (17.9)	77.42 (18.0)	0.46
FEV ₁ /FVC, mean (SD)	79.67 (5.1)	80.40 (5.2)	0.004	52.0 (12.4)	53.20 (11.5)	0.16
ECLIPSE						
n	103	75		1,182	582	
Age, yr, mean (SD)	58.4 (9.4)	56.3 (9.4)	0.14	64.0 (7.1)	62.9 (7.0)	0.001
Pack-years, mean (SD)	31.7 (23.5)	32.7 (26.7)	0.79	53.8 (29.4)	43.3 (21.3)	<0.001
Current smokers, n (%)	31 (30.4)	40 (53.3)	0.004	401 (34.7)	204 (36.0)	0.62
FEV ₁ pp, mean (SD)	107.9 (13.6)	107.9 (13.8)	0.97	46.4 (15.6)	50.1 (15.3)	<0.001
FVCpp, mean (SD)	108.35 (14.2)	115.50 (15.1)	0.002	82.95 (19.2)	91.03 (20.6)	<0.001
FEV ₁ /FVC, mean (SD)	78.86 (5.8)	79.51 (5.1)	0.44	43.85 (11.7)	46.36 (11.1)	<0.001
GenKOLS						
n	405	403		519	344	
Age, yr, mean (SD)	56.4 (10.0)	54.9 (9.4)	0.03	66.3 (10.0)	64.4 (9.9)	0.008
Pack-years, mean (SD)	21.8 (14.6)	17.5 (12.1)	<0.001	35.5 (19.6)	26.7 (15.1)	<0.001
Current smokers, n (%)	146 (36.1)	187 (46.4)	0.004	232 (44.7)	172 (50.0)	0.15
FEV ₁ pp, mean (SD)	94.4 (9.0)	95.4 (9.4)	0.15	50.7 (18.1)	50.5 (16.5)	0.86
FVCpp, mean (SD)	97.83 (9.7)	115.5 (15.1)	0.70	79.62 (18.9)	76.95 (15.7)	0.02
FEV ₁ /FVC, mean (SD)	78.82 (4.2)	79.33 (4.5)	0.10	50.69 (13.2)	52.33 (12.7)	0.07

Definition of abbreviations: COPDGene, Genetic Epidemiology of Chronic Obstructive Pulmonary Disease; ECLIPSE, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points; FEV₁pp, post-bronchodilator forced expiratory volume in 1 second % predicted; FVCpp, post-bronchodilator forced vital capacity % predicted; FEV₁/FVC: post-bronchodilator FEV₁:FVC ratio; GenKOLS, Genetics of Chronic Obstructive Lung Disease. Baseline characteristics of study subjects.

In a combined interaction model evaluating individual SNP-by-sex interactions, there was no evidence for association with COPD or SNP-by-sex interaction ($P=0.33$) for *CELSR1* in lifetime never-smokers in the Framingham Heart Study data.

Sex-Stratified Analysis of Top Interaction SNPs

We performed genetic association analysis stratified by sex for the top five interaction SNPs. The top SNP, rs9615358, in the gene, *CELSR1*, approached genome-wide significance for COPD affection status in females (odds ratio [OR], 1.37; 95% confidence interval [CI], 1.25–1.49; $P=3.32 \times 10^{-7}$), but not in males (OR, 0.90; 95% CI, 0.79–1.01; $P=0.06$) (Figure 1, Table 3). This genotyped SNP is located within an intronic region of the

gene *CELSR1*. The SNP, rs9615358, demonstrated evidence as a blood eQTL for *CELSR1* (30) ($P=0.0028$). This SNP is in linkage disequilibrium with the SNP, rs6008795 ($r^2=0.76$), which is predicted to cause a leucine-to-proline missense mutation (31). rs6008795 was nominally associated with COPD in the meta-analysis (females, $P=3.3 \times 10^{-4}$; males, $P=0.01$). The SNP, rs7294481, upstream from *FAR2*, was associated with a protective effect among male subjects (OR, 0.83 [95% CI, 0.74–0.92]; $P=2.49 \times 10^{-5}$), and an effect in the opposite direction among females (OR, 1.15 [95% CI, 1.06–1.25]; $P=0.003$) (Figure 2, Table 3).

Candidate Gene Analysis

We examined top SNPs from several genes/regions that have recently been

identified as associated with COPD affection status (*RIN3*, *FAM13A*, *HHIP*, *CHRNA3/IREB2*) and severe COPD (*MMP3/12*, *TGFB2*) (9). The SNP, rs754388, in the gene, *RIN3* locus demonstrated a nominally significant SNP-by-sex interaction ($P=0.03$) with a smaller P value and greater OR in females (OR, 1.41 [95% CI, 1.28–1.54]; $P=1.84 \times 10^{-7}$) compared with males (OR, 1.17 [95% CI, 1.05–1.28] $P=0.01$) (Table 4). The *FAM13A*, *HHIP*, *CHRNA3/IREB2*, *MMP3/12*, and *TGFB2* SNPs did not demonstrate significant SNP-by-sex interactions for the COPD case-control outcome.

Sex-Stratified GWAS

We additionally performed a sex-stratified GWAS testing all SNPs in all cohorts, and

Table 2. Single-Nucleotide Polymorphisms with P less than 10^{-6} for the Single-Nucleotide Polymorphism-by-Sex Interaction on COPD Case–Control Outcome

Chr	Gene	SNP	Reference Allele	MAF	Interaction P Value	Main Effect P Value
22	<i>CELSR1</i>	rs9615358	A	0.14	1.24×10^{-7}	0.04
9	<i>C9orf123</i>	rs7034632	T	0.33	2.95×10^{-7}	0.08
12	<i>FAR2</i>	rs7294481	T	0.42	3.00×10^{-7}	0.27
22	<i>CELSR1</i>	rs9615982	T	0.14	4.00×10^{-7}	0.27
22	<i>CELSR1</i>	rs7286446	T	0.14	5.49×10^{-7}	0.22
22	<i>CELSR1</i>	rs9615981	T	0.14	5.51×10^{-7}	0.22

Definition of abbreviations: Chr, chromosome; COPD, chronic obstructive pulmonary disease; MAF, minor allele frequency; SNP, single-nucleotide polymorphism.

P values from logistic regression for COPD case–control status, modeling the interaction between SNP and sex, and adjusted for age, pack-years, and principal components. Results from a meta-analysis, including COPDGene non-Hispanic white, COPDGene African American, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points, and Genetics of Chronic Obstructive Lung Disease subjects. Main effect P value represents result from logistic regression in the absence of the SNP \times sex interaction term.

then combined the results within each sex via meta-analysis (Tables E1 and E2). Among the female samples, the top sex-stratified GWAS results included several variants in the *FAM13A* locus that were associated with risk of COPD at the genome-wide level (rs2869966: OR, 1.35 [95% CI, 1.26–1.45]; $P = 6.63 \times 10^{-10}$). The P value for the association between these variants and COPD among the male samples was not as low (rs2869966: OR, 1.19 [95% CI, 1.10–1.28]; $P = 8.12 \times 10^{-5}$). The P value for the SNP-by-sex interaction for the top SNP, rs2869966, was 0.04. The top SNP among the males was rs56077333 in the gene, *CHRNA3* (OR, 1.35 [95% CI, 1.26–1.45]; $P = 1.61 \times 10^{-9}$). The P value for this SNP was not as low among female subjects (OR, 1.22 [95% CI, 1.12–1.33]; $P = 1.48 \times 10^{-4}$). The

SNP-by-sex interaction was not significant at a P value of 0.12.

Tissue Expression Data

Sexually dimorphic features in the lung may begin during lung development, and the gene, *CELSR1*, is involved in fetal lung maturity. As such, we examined the sex-specific expression of our top associated genes in a set of fetal lung tissue samples. In a linear regression model comparing tissue log expression levels and adjusting for age, the gene, *CELSR1*, was differentially expressed by sex, with significantly higher levels of expression in fetal lung tissue from females compared with fetal lung tissue from males (female log expression, 8.58; male log expression, 8.45; $P = 0.0007$; Figure E2). *FAR2* additionally demonstrated greater

expression in female fetal lung tissue compared with male fetal lung tissue (female log expression, 6.97; male log expression, 6.89; $P = 0.03$; Figure E3). Neither *CELSR1* nor *FAR2* was differentially expressed by COPD status in a comparison of 111 COPD case (59 female, 52 male) and 40 control (25 female, 15 male) adult human lung tissues ($P = 0.33$).

Discussion

This is the first GWAS, to our knowledge, to examine sexually dimorphic genetic risk factors for COPD. Our main findings show that the *CELSR1* gene is a candidate for COPD in female smokers. Variants in this gene approached genome-wide significance for a SNP-by-sex interaction for the outcome, COPD affection status. In a sex-stratified analysis, these SNPs were associated with COPD affection status among female subjects, but not among male subjects. *CELSR1* is a known early lung development gene; our top SNP appears to play a role in controlling *CELSR1* gene expression, and *CELSR1* gene expression was higher in female lung tissue from pseudoglandular and cannicular phases of lung development compared with male lung tissue. Collectively, these observations suggest that *CELSR1* may play a role in sexually dimorphic COPD susceptibility, and that this susceptibility may have developmental origins.

Several challenges exist to identifying sex-specific risk factors for complex traits. Early sex-specific association studies were




Figure 1. Regional association plots for *CELSR1* locus in (A) males and (B) females. This figure presents negative log P values for single-nucleotide polymorphisms (SNPs) within the region of the *CELSR1* gene from the linear regression model, testing the association between SNPs and chronic obstructive pulmonary disease (COPD) affection status in males and females separately. The top SNP (rs9615358) is marked in purple. chr, chromosome.

Table 3. Top Sex-Stratified Single-Nucleotide Polymorphisms in the Male and Female Stratified GWAS Study

SNP	Male Subjects		Female Subjects	
	Odds Ratio (95% CI)	P Value	Odds Ratio (95% CI)	P Value
<i>CELSR1</i> SNPs				
rs9615358	0.90 (0.79–1.01)	0.06	1.37 (1.25–1.49)	3.32×10^{-7}
rs9615982	0.86 (0.71–0.98)	0.01	1.31 (1.18–1.43)	2.08×10^{-5}
rs7286446	0.87 (0.76–0.98)	0.02	1.31 (1.18–1.43)	1.90×10^{-5}
rs9615981	0.87 (0.76–0.98)	0.02	1.31 (1.18–1.43)	1.89×10^{-5}
<i>FAR2</i> SNPs				
rs7294481	0.83 (0.74–0.92)	2.49×10^{-5}	1.15 (1.06–1.25)	0.003

Definition of abbreviations: CI, confidence interval; GWAS, genome-wide association; SNP, single-nucleotide polymorphism. Presenting sex-stratified analysis of the top SNPs from the SNP \times sex interaction test. SNP rs7034632 is excluded from this analysis, as the direction of the interaction effect was not uniform among all cohorts. This meta-analysis includes COPDGene non-Hispanic white and African American, Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points, and Genetics of Chronic Obstructive Lung Disease subjects, and is adjusted for age, pack-years, and principal components.

plagued with false-positive associations; one group demonstrated that, before 2007, most claims of a sex-difference in genetic effect were either spurious or insufficiently documented (32). Identification of a significant SNP-by-sex interaction requires more power than standard GWASs, and most cohorts assembled for the study of complex diseases lack sufficient sample size to overcome this. In contrast, sex-stratified genetic association tests that are performed in the absence of interaction testing are at increased risk for type 1 error. Lack of findings in one subgroup could be a result of chance or insufficient power to detect an association. Despite these

limitations, several recent studies have demonstrated sex-specific risk factors associated with complex traits using a combination of interaction and sex-stratified testing (11, 14). COPD is a disease with sexually dimorphic differences in susceptibility and presentation, and we therefore hypothesized that, similar to other complex diseases, there would be sexual dimorphism in the genetic architecture of this disease. To date, we are not aware of any other study that has investigated sexually dimorphic genetic risk factors for COPD at the genome-wide level. Genetic association studies of asthma, another

respiratory disease with dimorphic features, have demonstrated sex-specific effects. For example, in a recent analysis, Myers and colleagues (14) identified sex-specific associations with asthma in several genes, including *IRF-1* (5q31.1), using a combination of SNP-by-sex interaction testing and stratified association tests. For our analysis, we combined four large COPD case-control cohorts with sufficient female representation to perform two-stage testing, first testing for the SNP-by-sex interaction, then examining our top interaction SNPs in a sex-stratified analysis to identify risk alleles. Our findings identify variants that have biological plausibility for playing a role in sexually dimorphic features of COPD susceptibility.

The *CELSR1* gene encodes the cadherin EGF LAG seven-pass G-type receptor 1. *CELSR1* is involved in the planar cell polarity pathway of lung branching morphogenesis, and mice with *CELSR1* mutations demonstrate abnormal lung development, with smaller lungs and reduced branching compared with healthy lungs (33). Because this gene appears to play a role in lung development, we examined expression levels in human fetal lung tissue samples. We observed that this gene is dimorphically expressed in the human fetal lung. In our genome-wide SNP-by-sex testing, we found variants in the *CELSR1* gene that approached significance for an interaction by sex. Although these variants did not meet the prespecified threshold for genome-wide significance, the sex-stratified GWAS combining all four cohorts provides support that *CELSR1* may be involved in COPD risk for women, but not for men. This is further supported by our findings that *CELSR1* demonstrates differential expression by sex in the fetal lung. Although our most significant SNP is located within an intronic region in the gene, it is in close linkage disequilibrium with a missense SNP. The lung epithelial tube formation is coordinated by the planar cell polarity pathway, of which *CELSR1* plays an integral part. Therefore, it is possible that variants within this gene could lead to disruption of the actin-myosin lung cytoskeleton, as well as dysregulated branching morphogenesis. As seen in mouse models, this results in smaller lungs, with less epithelial branches and narrow or absent epithelia




Figure 2. Regional association plots for *FAR2* locus in (A) males and (B) females. This figure presents negative log *P* values for SNPs within the region of the *FAR2* gene from the linear regression model, testing the association between SNPs and COPD affection status in males and females separately. The top SNP (rs7294481) is marked in purple.

Table 4. Interaction and Sex-Stratified Results Published Top COPD GWAS Affection Alleles

Chr	Gene	SNP	Published <i>P</i> value	All Subjects Interaction <i>P</i> Value	Males <i>P</i> Value	Females <i>P</i> Value
15	<i>CHRNA3</i>	rs4416442	1.12×10^{-14}	0.08	1.68×10^{-5}	1.78×10^{-9}
4	<i>FAM13A</i>	rs12914385	6.38×10^{-14}	0.25	1.70×10^{-5}	3.30×10^{-5}
4	<i>HHIP</i>	rs13141641	1.57×10^{-12}	0.59	1.70×10^{-5}	3.72×10^{-6}
14	<i>RIN3</i>	rs754388	5.25×10^{-9}	0.03	1.04×10^{-2}	1.84×10^{-7}
11	<i>MMP3/12</i>	rs626750	5.35×10^{-9}	0.38	7.81×10^{-5}	1.82×10^{-2}
1	<i>TGFB2</i>	rs4846480	1.25×10^{-7}	0.86	2.48×10^{-3}	1.54×10^{-3}

Definition of abbreviations: COPD, chronic obstructive pulmonary disease; Chr, chromosome; GWAS, genome-wide association; SNP, single-nucleotide polymorphism.

Published *P* values are results from prior COPDGene affection status analysis (19); interaction *P* values are results from SNP \times sex interaction test for the outcome, COPD case-control status, including COPDGene non-Hispanic white and African American, ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points), and GenKOLS (Genetics of Chronic Obstructive Lung Disease) subjects. Male and female *P* values indicate results from male- and female-stratified meta-analysis of COPDGene non-Hispanic white, African American, ECLIPSE, and GenKOLS subjects. Results are from stratified logistic regression, adjusting for age, pack-years, and principal components.

(33). Small defects in lung size, branching, or the cytoskeleton scaffold could all predispose to smoking-related obstructive lung disease. The absence of association of COPD with *CELSR1* sequence variants among lifetime never-smokers suggests that the effects of these variants may influence susceptibility to postnatal exposures. Further work will be required to identify the functional variant or variants in this region and the mechanisms by which they may influence susceptibility to COPD.

COPD may have origins in early-life exposures and consequent developmental trajectories. Typically, among healthy nonsmokers, lung function achieves a peak in the second to third decade of life, followed by gradual decline. Several lung function trajectories have been identified that can lead to eventual obstructive disease, including rapid decline in lung function and lower peak lung function (34). Maternal and paternal behaviors, including cigarette smoke exposures, as well as recurrent respiratory infections, predispose to lower adult FEV₁ levels (35). Recent findings suggest that maximal lung function achieved in early adulthood may influence later development of COPD (36). Several studies suggest that women are more likely to develop COPD at an earlier age (6), and with less exposure to cigarettes (8), suggesting that lung development may play a role in women's risk of COPD. It is possible that variants in the *CELSR1* gene could be responsible for sexually dimorphic response to early-life exposures through altering the size, morphology, and actin-myosin

cytoskeleton of female lungs. We only observe statistically significant gene expression differences of *CELSR1* by sex in fetal lung tissue. In an adult lung tissue expression dataset of cases with COPD and control subjects, we do not observe differential expression of *CELSR1* or *FAR2*. In a prior sex-stratified analysis of gene expression in subjects with COPD, we broadly observed that there was limited differential gene expression by sex, but extensive differential gene regulation by sex (37). From those data, we observe that *CELSR1* is strongly differentially targeted in a female-only COPD gene expression network compared with a male-only COPD gene expression network (false discovery rate adjusted $P = 2.3 \times 10^{-9}$), suggesting a potential sexually dimorphic contribution by *CELSR1* to COPD through sex-specific gene regulation, not necessarily gene expression.

We additionally identified several variants upstream from the *FAR2* gene that also approached significance for an association with COPD affection status. The effect estimate for these SNPs was in the opposite direction for males and females, but the overall *P* value in the sex-stratified analysis did not meet the prespecified genome-wide significance threshold. There was a modest increased expression of this gene among female subjects in the fetal lung expression dataset. The role of the *FAR2* gene product has not been well described. Modest expression has been identified in pneumocytes and lung endothelial cells (38). The pattern on differential gene

targeting by sex observed for *CELSR1* was not observed for *FAR2*.

The candidate gene analysis of known COPD genes and sex-stratified GWASs did not identify significant sex-based differences in known COPD genes; however, there were some interesting differences in how these variants were associated within each sex. We found that previously identified variants upstream from *RIN3* did demonstrate a significant SNP-by-sex interaction in our candidate gene approach. The *P* value for this variant was much lower among female subjects than male subjects; however, the effect size and direction of effect were similar between both groups. The sex-stratified analysis identified known COPD SNPs within the top genome-wide significant SNPs for each sex; however, different SNPs rose to the top for each sex. Among the females, SNPs in the gene, *FAM13A*, were significant for COPD. The effect size was in the same direction in both groups, but of greater magnitude among females. The SNP-by-sex interaction was 0.04 for the top SNP, which did not reach genome-wide significance. GWASs have previously demonstrated that this gene is associated with COPD (9, 19) as well as with lung function (39). The sex-stratified approach is essentially a subset analysis; our findings could be related to differences in power to detect an association between the two groups. Alternatively, they could suggest sexually dimorphic associations between these variants that would be better demonstrated through more functional approaches.

Our study has several limitations. First, interaction testing requires very large sample sizes to achieve adequate power. We were limited by the availability of adequate COPD case-control datasets with sufficient female subjects, and therefore did not identify any variants that met the prespecified genome-wide threshold for a significant interaction. However, the gene, *CELSR1*, had many SNPs that approached this threshold and demonstrated differences in association between males and females, and we found supportive evidence of sexually dimorphic expression in the developing lung. This analysis highlights the need for greater inclusion of women in COPD cohorts, and future studies with larger sample sizes may better identify SNP-by-sex interactions. Functional follow-up studies will better identify the mechanisms behind these identified differences. Second, female subjects with COPD in our analysis were younger and had less cumulative smoking exposure (pack-years), although we did adjust for this by including age and pack-years as covariates in our model. Third, we used all available cohorts that had suitable populations of males and females for this analysis. Therefore, we do not have an additional population to replicate our top finding. As additional cohorts are developed that include greater participation of female subjects, future studies can include replication of our findings here.

Finally, racial differences have been demonstrated in COPD susceptibility and presentation (7). Other analyses of COPD-related phenotypes in this population have identified risk variants in the African American population that were not present among the non-Hispanic white population, although these risk alleles were rare (40). We included the African American subjects in our meta-analysis of SNP-by-sex interaction and case-control affection status, as has been done previously (9, 40). However, our study size is underpowered to identify SNP-by-sex interactions among the African American population alone in this study. There is a need to develop more data from African American genotyped populations to better study race-specific sexually dimorphic risk factors for COPD.

In conclusion, this is the first GWAS to identify sex-specific genetic risk factors for

COPD. We identified variants in the lung development gene, *CELSR1*, that are associated with COPD in women, but not men. These findings could identify potential pathways for developmental origins of chronic airflow obstruction among women. ■

Author disclosures are available with the text of this article at www.atsjournals.org.

COPD Gene Investigators—Core Units

Administrative Core: James D. Crapo, M.D. (Principal Investigator [PI]), Edwin Silverman, M.D., Ph.D. (PI), Barry Make, M.D., Elizabeth Regan, M.D., Ph.D.

Genetic Analysis Core: Terri Beaty, Ph.D., Nan Laird, Ph.D., Christoph Lange, Ph.D., Michael Cho, M.D., Stephanie Santorico, Ph.D., John Hokanson, M.P.H., Ph.D., Dawn DeMeo, M.D., M.P.H., Nadia Hansel, M.D., M.P.H., Craig Hersh, M.D., M.P.H., Peter Castaldi, M.D., M.Sc., Merry-Lynn McDonald, Ph.D., Emily Wan, M.D., Megan Hardin, M.D., Jacqueline Hetmanski, M.S., Margaret Parker, M.S., Marilyn Foreman, M.D., Brian Hobbs, M.D., Robert Busch, M.D., Adel El-Boueiz, M.D., Peter Castaldi, M.D., Megan Hardin, M.D., Dandi Qiao, Ph.D., Elizabeth Regan, M.D., Eitan Halper-Stromberg, Ferdouse Begum, Sungho Won, Sharon Lutz, Ph.D.

Imaging Core: David A. Lynch, M.D., Harvey O. Coxson, Ph.D., Mei-Lan K. Han, M.D., M.S., Eric A. Hoffman, Ph.D., Stephen Humphries M.S., Francine L. Jacobson, M.D., Philip F. Judy, Ph.D., Ella A. Kazerooni, M.D., John D. Newell Jr., M.D., Elizabeth Regan, M.D., James C. Ross, Ph.D., Raul San Jose Estepar, Ph.D., Berend C. Stoel, Ph.D., Juerg Tschirren, Ph.D., Eva van Rikxoort, Ph.D., Bram van Ginneken, Ph.D., George Washko, M.D., Carla G. Wilson, M.S., Mustafa Al Qaisi, M.D., Teresa Gray, Alex Kluiber, Tanya Mann, Jered Sieren, Douglas Stinson, Joyce Schroeder, M.D., Edwin Van Beek, M.D., Ph.D.

PFT QA Core, Salt Lake City, Utah: Robert Jensen, Ph.D.

Data Coordinating Center and Biostatistics, National Jewish Health, Denver, Colorado: Douglas Everett, Ph.D., Anna Faino, M.S., Matt Strand, Ph.D., Carla Wilson, M.S.

Epidemiology Core, University of Colorado Anschutz Medical Campus, Aurora, Colorado: John E. Hokanson, M.P.H., Ph.D., Gregory Kinney, M.P.H., Ph.D., Sharon Lutz, Ph.D., Kendra Young Ph.D., Katherine Pratte, M.S.P.H., Lindsey Duca, M.S.

COPD Gene Investigators—Clinical Centers

Ann Arbor Veterans Administration, Ann Arbor, Michigan: Jeffrey L. Curtis, M.D., Carlos H. Martinez, M.D., M.P.H., Perry G. Pernicano, M.D.

Baylor College of Medicine, Houston, Texas: Nicola Hanania, M.D., M.S., Philip Alapat, M.D., Venkata Bandi, M.D., Mustafa Atik, M.D., Aladin Boriek, Ph.D., Kalpatha Guntupalli, M.D., Elizabeth Guy, M.D., Amit Parulekar, M.D., Arun Nachiappan, M.D.

Brigham and Women's Hospital, Boston, Massachusetts: Dawn DeMeo, M.D., M.P.H.,

Craig Hersh, M.D., M.P.H., George Washko, M.D., Francine Jacobson, M.D., M.P.H.

Columbia University, New York, New York: R. Graham Barr, M.D., Dr.P.H., Byron Thomashow, M.D., John Austin, M.D., Belinda D'Souza, M.D., Gregory D. N. Pearson, M.D., Anna Rozenshtein, M.D., M.P.H.

Duke University Medical Center, Durham, North Carolina: Neil MacIntyre Jr., M.D., Lacey Washington, M.D., H. Page McAdams, M.D.

Health Partners Research Foundation, Minneapolis, Minnesota: Charlene McEvoy, M.D., M.P.H., Joseph Tashjian, M.D.

Johns Hopkins University, Baltimore, Maryland: Robert Wise, M.D., Nadia Hansel, M.D., M.P.H., Robert Brown, M.D., Karen Horton, M.D., Nirupama Putcha, M.D., M.H.S.

Los Angeles Biomedical Research Institute at Harbor University of California Los Angeles Medical Center, Torrance, California: Richard Casaburi, Ph.D., M.D., Alessandra Adami, Ph.D., Janos Porszasz, M.D., Ph.D., Hans Fischer, M.D., Ph.D., Matthew Budoff, M.D., Harry Rossiter, Ph.D.

Michael E. DeBakey VAMC, Houston, TX: Amir Sharafkhaneh, M.D., Ph.D., Charlie Lan, D.O.

Minneapolis Veterans Affairs, Minneapolis, Minnesota: Christine Wendt, M.D., Brian Bell, M.D.

Morehouse School of Medicine, Atlanta, Georgia: Marilyn Foreman, M.D., M.S., Gloria Westney, M.D., M.S., Eugene Berkowitz, M.D., Ph.D.

National Jewish Health, Denver, Colorado: Russell Bowler, M.D., Ph.D., David Lynch, M.D.

Reliant Medical Group, Worcester, Massachusetts: Richard Rosiello, M.D., David Pace, M.D.

Temple University, Philadelphia, Pennsylvania: Gerard Criner, M.D., David Ciccolella, M.D., Francis Cordova, M.D., Chandra Dass, M.D., Gilbert D'Alonzo, D.O., Parag Desai, M.D., Michael Jacobs, Pharm.D., Steven Kelsen, M.D., Ph.D., Victor Kim, M.D., A. James Mamary, M.D., Nathaniel Marchetti, D.O., Aditi Satti, M.D., Kartik Shenoy, M.D., Robert M. Steiner, M.D., Alex Swift, M.D., Irene Swift, M.D., Maria Elena Vega-Sanchez, M.D.

University of Alabama, Birmingham, Alabama: Mark Dransfield, M.D., William Bailey, M.D., J. Michael Wells, M.D., Surya Bhatt, M.D., Hrudaya Nath, M.D.

University of California, San Diego, California: Joe Ramsdell, M.D., Paul Friedman, M.D., Xavier Soler, M.D., Ph.D., Andrew Yen, M.D.

University of Iowa, Iowa City, Iowa: Alejandro Cornellas, M.D., John Newell Jr., M.D., Brad Thompson, M.D.

University of Michigan, Ann Arbor, Michigan: Mei-Lan Han, M.D., Ella Kazerooni, M.D., Carlos Martinez, M.D.

University of Minnesota, Minneapolis, Minnesota: Joanne Billings, M.D., Tadashi Allen, M.D.

University of Pittsburgh, Pittsburgh, Pennsylvania: Frank Sciruba, M.D., Divay Chandra, M.D., M.Sc., Joel Weissfeld, M.D., M.P.H., Carl Fuhrman, M.D., Jessica Bon, M.D.

University of Texas Health Science Center at San Antonio, San Antonio, Texas: Antonio Anzueto, M.D., Sandra Adams, M.D., Diego Maselli-Caceres, M.D., Mario E. Ruiz, M.D.

References

- Hoyert DLXJ, Xu J. Deaths: preliminary data for 2011. *Natl Vital Stat Rep* 2012;61:1–51.
- Morbidity and Mortality Weekly Report 2012. 61(46):938–943.
- Pinkerton KE, Harbaugh M, Han MK, Jourdan Le Saux C, Van Winkle LS, Martin WJ II, Kosgei RJ, Carter EJ, Sitkin N, Smiley-Jewell SM, *et al.* Women and lung disease: sex differences and global health disparities. *Am J Respir Crit Care Med* 2015;192:11–16.
- Martinez FJ, Curtis JL, Sciurba F, Mumford J, Giardino ND, Weinmann G, Kazerooni E, Murray S, Criner GJ, Sin DD, *et al.*; National Emphysema Treatment Trial Research Group. Sex differences in severe pulmonary emphysema. *Am J Respir Crit Care Med* 2007;176:243–252.
- Hardin M, Foreman M, Dransfield MT, Hansel N, Han MK, Cho MH, Bhatt SP, Ramsdell J, Lynch D, Curtis JL, *et al.*; COPDGene Investigators. Sex-specific features of emphysema among current and former smokers with COPD. *Eur Respir J* 2016;47:104–112.
- Silverman EK, Weiss ST, Drazen JM, Chapman HA, Carey V, Campbell EJ, Denish P, Silverman RA, Celedon JC, Reilly JJ, *et al.* Gender-related differences in severe, early-onset chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2000;162:2152–2158.
- Foreman MG, Zhang L, Murphy J, Hansel NN, Make B, Hokanson JE, Washko G, Regan EA, Crapo JD, Silverman EK, *et al.*; COPDGene Investigators. Early-onset chronic obstructive pulmonary disease is associated with female sex, maternal factors, and African American race in the COPDGene Study. *Am J Respir Crit Care Med* 2011;184:414–420.
- Sorheim IC, Johannessen A, Gulsvik A, Bakke PS, Silverman EK, DeMeo DL. Gender differences in COPD: are women more susceptible to smoking effects than men? *Thorax* 2010;65:480–485.
- Cho MH, McDonald ML, Zhou X, Mattheisen M, Castaldi PJ, Hersh CP, DeMeo DL, Sylvia JS, Ziniti J, Laird NM, *et al.*; NETT Genetics, ICGN, ECLIPSE and COPDGene Investigators. Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. *Lancet Respir Med* 2014;2:214–225.
- Ober C, Loisel DA, Gilad Y. Sex-specific genetic architecture of human disease. *Nat Rev Genet* 2008;9:911–922.
- Gilks WP, Abbott JK, Morrow EH. Sex differences in disease genetics: evidence, evolution, and detection. *Trends Genet* 2014;30:453–463.
- Heid IM, Jackson AU, Randall JC, Winkler TW, Qi L, Steinthorsdottir V, Thorleifsson G, Zillikens MC, Speliotes EK, Mägi R, *et al.*; MAGIC. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. *Nat Genet* 2010;42:949–960.
- Morris AP, Voight BF, Teslovich TM, Ferreira T, Segrè AV, Steinthorsdottir V, Strawbridge RJ, Khan H, Grallert H, Mahajan A, *et al.*; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network–Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nat Genet* 2012;44:981–990.
- Myers RA, Scott NM, Gauderman WJ, Qiu W, Mathias RA, Romieu I, Levin AM, Pino-Yanes M, Graves PE, Villarreal AB, *et al.*; GRAAD. Genome-wide interaction studies reveal sex-specific asthma risk alleles. *Hum Mol Genet* 2014;23:5251–5259.
- Pan L, Ober C, Abney M. Heritability estimation of sex-specific effects on human quantitative traits. *Genet Epidemiol* 2007;31:338–347.
- Kim WJ, Wood AM, Barker AF, Brantly ML, Campbell EJ, Eden E, McElvaney G, Rennard SI, Sandhaus RA, Stocks JM, *et al.* Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in severe alpha-1 antitrypsin deficiency. *Respir Res* 2012;13:16.
- Regan EA, Hokanson JE, Murphy JR, Make B, Lynch DA, Beaty TH, Curran-Everett D, Silverman EK, Crapo JD. Genetic epidemiology of COPD (COPDGene) study design. *COPD* 2010;7:32–43.
- Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, MacNee W, *et al.*; ECLIPSE investigators. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-Points (ECLIPSE). *Eur Respir J* 2008;31:869–873.
- Cho MH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, Hersh CP, DeMeo DL, Hunninghake GM, Litonjua AA, Sparrow D, *et al.* Variants in FAM13A are associated with chronic obstructive pulmonary disease. *Nat Genet* 2010;42:200–202.
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, *et al.*; ATS/ERS Task Force. Standardisation of spirometry. *Eur Respir J* 2005;26:319–338.
- Cho MH, Castaldi PJ, Wan ES, Siedlinski M, Hersh CP, DeMeo DL, Himes BE, Sylvia JS, Klanderman BJ, Ziniti JP, *et al.*; ICGN Investigators; ECLIPSE Investigators; COPDGene Investigators. A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. *Hum Mol Genet* 2012;21:947–957.
- Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, *et al.*; ICGN Investigators. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. *PLoS Genet* 2009;5:e1000421.
- Aulchenko YS, Struchalin MV, van Duijn CM. ProbABEL package for genome-wide association analysis of imputed data. *BMC Bioinformatics* 2010;11:134.
- Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 2015;4:7.
- Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 2010;26:2190–2191.
- Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Glied TP, Boehnke M, Abecasis GR, Willer CJ. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* 2010;26:2336–2337.
- Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. *Bioinformatics* 2008;24:2938–2939.
- Sharma S, Tantisira K, Carey V, Murphy AJ, Lasky-Su J, Celedón JC, Lazarus R, Klanderman B, Rogers A, Soto-Quirós M, *et al.* A role for Wnt signaling genes in the pathogenesis of impaired lung function in asthma. *Am J Respir Crit Care Med* 2010;181:328–336.
- Vyhlidal CA, Riffel AK, Haley KJ, Sharma S, Dai H, Tantisira KG, Weiss ST, Leeder JS. Cotinine in human placenta predicts induction of gene expression in fetal tissues. *Drug Metab Dispos* 2013;41:305–311.
- Castaldi PJ, Cho MH, Zhou X, Qiu W, Mcgeachie M, Celli B, Bakke P, Gulsvik A, Lomas DA, Crapo JD, *et al.* Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci. *Hum Mol Genet* 2015;24:1200–1210.
- Artimo P, Jonnalagedda M, Arnold K, Baratin D, Csardi G, de Castro E, Duvaud S, Flegel V, Fortier A, Gasteiger E, *et al.* ExPASy: SIB bioinformatics resource portal. *Nucleic Acids Res* 2012;40(Web Server issue):W597–W603.
- Patsopoulos NA, Tatsioni A, Ioannidis JP. Claims of sex differences: an empirical assessment in genetic associations. *JAMA* 2007;298:880–893.
- Yates LL, Schnatwinkel C, Murdoch JN, Bogani D, Formstone CJ, Townsend S, Greenfield A, Niswander LA, Dean CH. The PCP genes *Celsr1* and *Vangl2* are required for normal lung branching morphogenesis. *Hum Mol Genet* 2010;19:2251–2267.
- Weiss ST, Ware JH. Overview of issues in the longitudinal analysis of respiratory data. *Am J Respir Crit Care Med* 1996;154:S208–S211.
- Svanes C, Sunyer J, Plana E, Dharmage S, Heinrich J, Jarvis D, de Marco R, Norbäck D, Raheerison C, Villani S, *et al.* Early life origins of chronic obstructive pulmonary disease. *Thorax* 2010;65:14–20.

36. Lange P, Celli B, Agustí A, Boje Jensen G, Divo M, Faner R, Guerra S, Marott JL, Martinez FD, Martinez-Camblor P, *et al.* Lung-function trajectories leading to chronic obstructive pulmonary disease. *N Engl J Med* 2015;373:111–122.
37. Glass K, Quackenbush J, Silverman EK, Celli B, Rennard SI, Yuan GC, DeMeo DL. Sexually-dimorphic targeting of functionally related genes in COPD. *BMC Syst Biol* 2014;8:118.
38. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, *et al.* Proteomics: tissue-based map of the human proteome. *Science* 2015;347:1260419.
39. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marcante KD, Franceschini N, van Durme YM, Chen TH, Barr RG, *et al.* Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. *Nat Genet* 2010; 42:45–52.
40. McDonald ML, Cho MH, Sørheim IC, Lutz SM, Castaldi PJ, Lomas DA, Coxson HO, Edwards LD, MacNee W, Vestbo J, *et al.*; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints and COPDGene Investigators. Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease. *Am J Respir Cell Mol Biol* 2014;51:678–687.